Clinical trials: Cryptogenic Epilepsy
Epilepsy
CX-8998 for Absence Seizures
This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period…
- Trial name
- T-WAVE (NCT03406702)
- Testing
- CX-8998
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
The purpose is to assess the safety of Lacosamide in subjects with uncontrolled Primary Generalized Tonic-Clonic (PGTC) seizures with Idiopathic Generalized Epilepsy.
- Trial name
- NCT01118949
- Testing
- Lacosamide
- Where
- 25 sites in United States
- Volunteers
- 49 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Focal Onset Seizure, Primary Generalized Epilepsy
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
- Trial name
- NCT06908356
- Testing
- 30mg PRAX-628
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 50 people
- Sponsor
- Praxis Precision Medicines
Allergic Asthma
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
This study will evaluate the efficacy of QGE031 compared to omalizumab in patients with allergic asthma. Each treatment's effect in changing the concentration of inhaled allergen that is required to elicit a 15% fall in the…
- Trial name
- NCT01703312
- Testing
- QGE031, omalizumab
- Where
- 7 sites in Canada, Sweden
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Primary Generalized Epilepsy
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures.
- Trial name
- NCT03678753
- Testing
- Cenobamate
- Where
- 116 sites in United States, Australia and 10 more
- Volunteers
- 169 people
- Sponsor
- SK Life Science, Inc.
Epilepsy, Idiopathic Generalized Epilepsy
RNS System NAUTILUS Study
To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant…
- Conditions
- Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
- Trial name
- NAUTILUS (NCT05147571)
- Testing
- Responsive stimulation
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroPace
Generalized Convulsive Epilepsy
Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults
A double-blind, placebo-controlled study to assess the efficacy of adjunctive treatment with LEV 3000mg/day in reducing myoclonic seizures in adolescents and adults suffering from idiopathic generalised epilepsy and to evaluate…
- Trial name
- NCT00150774
- Testing
- Levetiracetam
- Volunteers
- 116 people
- Sponsor
- UCB Pharma
Epilepsy
Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
This study is intended to provide evidence that zonisamide is safe and effective in the treatment of myoclonic seizures. The total planned trial duration will be 6.5 months.
- Trial name
- NCT00693017
- Testing
- Zonisamide
- Where
- 72 sites in Australia, Croatia and 11 more
- Volunteers
- 10 people
- Sponsor
- Eisai Limited
Asthma
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00219323
- Testing
- Omalizumab
- Where
- Japan
- Volunteers
- 133 people
- Sponsor
- Novartis
Epilepsy
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects >= 4 years of age with idiopathic generalized epilepsy…
- Trial name
- VALUE (NCT02408549)
- Testing
- Lacosamide Tablet, Lacosamide Oral Solution
- Where
- 87 sites in United States, Australia and 19 more
- Volunteers
- 239 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Infantile Spasms, Refractory Complex Partial Seizures in Adults
Sabril Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with Sabril and the prescribers of Sabril.
- Trial name
- NCT01073579
- Testing
- Sabril®
- Volunteers
- 9,423 people
- Sponsor
- Lundbeck LLC
Epilepsy
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy…
- Trial name
- VALOR (NCT02408523)
- Testing
- Lacosamide Tablet, Lasosamide Oral Solution
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 242 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Cow's Milk Allergy
Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.
The aim of this interventional study is to assess the hypoallergenicity of a new formula in infants having a cow milk allergy (CMA), whatever the type of CMA, meaning in both IgE-mediated and non-IgE-mediated CMA patients.
- Trial name
- MERLIN (NCT06481280)
- Testing
- Test Formula
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 70 people
- Sponsor
- United Pharmaceuticals
Allergic Asthma
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that…
- Trial name
- NCT00267202
- Testing
- Omalizumab, Immunotherapy
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis
Epilepsy
A Study of Fycompa (Perampanel) in Korean Participants
The purpose of this post-marketing surveillance is to observe the following items regarding the safety profile of Fycompa (Perampanel) film-coated tablets and oral suspension in normal clinical practice setting: serious adverse…
- Trial name
- NCT02722590
- Where
- 9 sites in South Korea
- Volunteers
- 3,692 people
- Sponsor
- Eisai Korea Inc.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Epilepsy
Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy.
- Trial name
- NCT01118962
- Testing
- Lacosamide
- Where
- 19 sites in United States
- Volunteers
- 39 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Idiopathic Generalized Epilepsy, Partial Onset Seizures
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial…
- Conditions
- Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
- Trial name
- NCT04252846
- Testing
- Perampanel
- Where
- 36 sites in Denmark, France and 5 more
- Volunteers
- 191 people
- Sponsor
- Eisai Limited
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Cenobamate Open-Label Extension Study for YKP3089C025
52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)
- Trial name
- NCT03961568
- Testing
- Cenobamate
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- SK Life Science, Inc.